Overview

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Leiden University Medical Center
Treatments:
Niacinamide
Sorafenib